

SUPPORTING INFORMATION

Interception of Secondary Amide Ylide with Sulfonamides: Catalyst Controlled Synthesis of N-sulfonyl Amidines Derivatives

Jijun Chen, Wenhao Long, Yonggang Yang* and Xiaobing Wan*

*Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry,
Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, P.*

R. China

Email: wanxb@suda.edu.cn

List of contents

General Information.....	S2
General Procedures for Reactions.....	S2
Optimization of the Reaction Conditions.....	S4
Mechanistic Probes.....	S5
Compound characterizations.....	S7
References.....	S36
Spectroscopic data for products.....	S37
XRD data of the compound 4a, 4l, 5a, and 5k.....	S101

General Information

All manipulations were carried out under air atmosphere. Column chromatography was generally performed on silica gel (300-400 mesh) and reactions were monitored by thin layer chromatography (TLC) using UV light to visualize the course of the reactions. The ^1H NMR (400MHz) and ^{13}C NMR (100MHz) data were recorded using CDCl_3 as solvent at room temperature unless specified otherwise. ^{19}F NMR (376 MHz) data was recorded using CDCl_3 as solvent at room temperature. The chemical shifts (δ) are reported in ppm and coupling constants (J) in Hz. ^1H NMR spectra was recorded with tetramethylsilane ($\delta = 0.00$ ppm) as internal reference; ^{13}C NMR spectra was recorded with CDCl_3 ($\delta = 77.00$ ppm) as internal reference. IR, HRMS, GC, and X-ray were performed by the State-authorized Analytical Center in Soochow University.

General procedures for reactions

(a) The procedure for the synthesis of diazo compounds¹

The corresponding alcohol (20 mmol) and NaHCO_3 (5.0 g, 60 mmol) were dissolved in acetonitrile (50 mL) and bromoacetyl bromide (2.6 mL, 30 mmol) was added slowly at $0\text{ }^\circ\text{C}$. After stirring 30 min at the temperature, the reaction was quenched with H_2O . The solution was extracted with CH_2Cl_2 three times. The organic phase was washed with brine and dried over Na_2SO_4 . The solvent was evaporated, and the residue was used in the next reaction without purification. The bromoacetate thus obtained and N,N' -ditosylhydrazine (13.6 g, 40 mmol) were dissolved in THF (50 mL) and cooled to $0\text{ }^\circ\text{C}$. DBU (60 mL, 40 mmol) was added dropwise and stirred at the temperature for 30 minutes. After the quenching of the reaction by the addition of saturated NaHCO_3 solution, it was extracted with Et_2O three times. The organic phase was washed with brine, dried over Na_2SO_4 and evaporated to give the crude product. The crude product thus obtained was purified by chromatography over a column of silica gel using petroleum and ethyl acetate as eluent to afford the desired product.

(b) The procedure for the synthesis of *N*-sulfonyl amidines under manganese catalysis

Mn(ClO₄)₂·6H₂O (0.02 mmol), secondary amides (0.2 mmol), and sulfamides (0.2 mmol) were added to a 20 mL test tube with a stirring bar. Cyclohexane (0.5 mL), diazo compounds (0.4 mmol) were added via syringe. The reaction mixture was heated in an oil bath at reflux (Tips: severe reflux, recommendation temperature: 90 °C) for 12 h under air (Tips: sometimes the solvent might evaporate, but the yield of *N*-sulfonyl amidines will barely be affected). After, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using petroleum ether/ ethylacetate to give the desired products.

(c) The procedure for the synthesis of *N*-sulfonyl amidines under zinc catalysis

Zn(OTf)₂ (0.06 mmol), secondary amides (0.2 mmol), and sulfamides (0.2 mmol) were added to a 20 mL test tube with a stirring bar. Cyclohexane (0.5 mL) and diazo compounds (1.2 mmol) were added via syringe. The reaction mixture was heated in an oil bath at reflux (Tips: severe reflux, recommendation temperature: 90 °C) for 12 h under air (Tips: sometimes the solvent might evaporate, but the yield of *N*-sulfonyl amidines will barely be affected). After, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using petroleum ether/ ethylacetate to give the desired products.




(Tips: In many cases, *N*-sulfonyl amidines slightly soluble in ethyl acetate, soluble in dichloromethane)


Table S1. Optimization of the Reaction Conditions^a

1a	2a	3a	catalyst (x mol %) C ₆ H ₁₂ (0.5 mL) air, reflux, 12 h	4a	5a
entry	catalyst	x	3a (equiv)	4a yield (%) ^b	5a yield (%) ^b
1	Zn(OTf) ₂	10	2	29	30
2	ZnCl ₂	10	2	21	< 5
3	ZnBr ₂	10	2	21	< 5
4	Cu(acac) ₂	10	2	19	< 5
5	Co(BF ₄) ₂ ·6H ₂ O	10	2	38	8
6	AgOTf	10	2	24	< 5
7	Fe(OTf) ₃	10	2	44	21
8	Mn(ClO ₄) ₂ ·6H ₂ O	10	2	63	< 5
9	Ni(ClO ₄) ₂ ·6H ₂ O	10	2	21	< 5
10	Zn(ClO ₄) ₂ ·6H ₂ O	10	2	47	< 5
11	AgClO ₄	10	2	< 5	< 5
12	Zn(OTf) ₂	10	3	11	59
13	Zn(OTf) ₂	10	4	10	61
14	Zn(OTf) ₂	20	4	< 5	61
15	Zn(OTf) ₂	30	4	< 5	56
16	Zn(OTf) ₂	30	5	< 5	66
17	Zn(OTf) ₂	30	6	< 5	81
18	—	—	2	< 5	< 5
19	Zn(OTf) ₂	10	—	< 5	< 5
20	Mn(ClO ₄) ₂ ·6H ₂ O	10	—	< 5	< 5


^aReaction Conditions: **1a** (0.2 mmol), **2a** (0.2 mmol), **3a**, and catalyst in C₆H₁₂ (0.5 mL) at reflux for 12 h under air, isolated yield.

Carbene traps experiment:







Compound Characterizations




***N*-phenyl-*N'*-tosylacetimidamide (4a).** Petroleum ether/ ethylacetate = 3:1, white solid, 36.5 mg, 63% yield, *E/Z* = 1:1.5. ^1H NMR (400 MHz, CDCl_3) δ 9.85 (s, 0.67H), 8.36 (s, 1H), 7.87–7.86 (m, 1.34H), 7.79–7.77 (m, 2H), 7.54–7.52 (m, 2H), 7.43–7.39 (m, 1.33H), 7.36–7.35 (m, 0.66H), 7.32–7.30 (m, 1H), 7.25–7.19 (m, 4H), 7.13–7.06 (m, 2.65H), 2.51 (s, 3H), 2.42 (s, 2H), 2.39 (s, 3H), 2.03 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 163.6, 143.3, 142.4, 140.0, 138.8, 137.3, 136.3, 129.6, 129.4, 129.2, 128.6, 128.1, 126.4, 126.23, 126.17, 125.3, 121.8, 21.8, 21.5, 21.4. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_2\text{S}+\text{Na}^+$: 311.0825, Found: 311.0828; IR (neat, cm^{-1}): ν 3302, 1531, 1268, 1137, 1085, 688.




***N'*-tosyl-*N*-(4-(trifluoromethyl)phenyl)acetimidamide (4b).** Petroleum ether/ ethylacetate = 4:1, 45.3 mg, white solid, 64% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, DMSO) δ 10.27 (s, 1H), 8.09 (s, 1H), 7.77–7.75 (m, 1H), 7.73–7.71 (m, 2H), 7.54–7.50 (m, 1H), 7.36–7.34 (m, 2H), 7.28 (s, 1H), 2.36 (s, 3H), 2.08 (s, 3H). ^{13}C NMR (101 MHz, DMSO) δ 168.9, 141.9, 141.5, 140.1, 129.9, 129.3, 125.7, 122.4, 119.3 ((q, J = 3 Hz)), 115.0, 24.0, 20.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{16}\text{H}_{15}\text{F}_3\text{N}_2\text{O}_2\text{S}+\text{Na}^+$: 357.0879, Found: 357.0871; IR (neat, cm^{-1}): ν 3272, 1676, 1557, 1331, 1157, 662.



***N*-benzyl-*N'*-tosylacetimidamide (4c).** Petroleum ether/ ethylacetate = 2:1, white solid, 44.8 mg, 74% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.65–7.63 (m, 2H), 7.24–7.23 (m, 3H), 7.19–7.17 (m, 4H), 6.99 (s, 1H), 4.39 (d, *J* = 2.1 Hz, 2H), 2.38 (s, 3H), 2.28 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.8, 142.1, 140.3, 136.5, 129.1, 128.5, 128.0, 127.5, 126.1, 45.8, 21.3, 20.7. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{S}+\text{Na}^+$: 325.0981, Found: 325.0973; IR (neat, cm^{-1}): ν 3304, 1542, 1270, 1143, 1088, 668.




***N*-methyl-*N'*-tosylacetimidamide (4d).** Petroleum ether/ ethylacetate = 1:1, white solid, 34.6 mg, 77% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.77–7.75 (m, 2H), 7.26–7.24 (m, 2H), 7.02 (s, 1H), 2.80 (s, 3H), 2.39 (s, 3H), 2.27 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.8, 142.2, 140.3, 129.2, 126.2, 28.8, 21.4, 20.6. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_2\text{S}+\text{Na}^+$: 249.0668, Found: 249.0658; IR (neat, cm^{-1}): ν 3294, 1554, 1271, 1139, 665.




***N*-methyl-*N'*-tosylbenzimidamide (4e).** Petroleum ether/ ethylacetate = 2:1, white solid, 23.7 mg, 41% yield, *E/Z* = 1:1. ^1H NMR (400 MHz, CDCl_3) δ 8.50 (s, 1H), 7.84–7.83 (m, 2H), 7.63–7.61 (m, 2H), 7.49–7.41 (m, 9H), 7.35–7.33 (m, 2H), 7.28 (s,

1H), 7.16–7.14 (m, 2H), 5.90 (s, 1H), 2.98 (s, 3H), 2.94 (s, 3H), 2.41 (s, 3H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.7, 166.3, 142.9, 141.7, 140.8, 139.2, 134.2, 132.5, 131.0, 130.7, 129.3, 128.8, 128.5, 128.1, 128.0, 127.7, 126.42, 126.40, 33.0, 29.5, 21.5, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C₁₅H₁₆N₂O₂S+Na⁺: 311.0825, Found: 311.0824; IR (neat, cm⁻¹): ν 3257, 1535, 1268, 1134, 1080, 687.




N-benzyl-N'-tosylbenzimidamide (4f). Petroleum ether/ ethylacetate = 3.5:1, colorless liquid, 42.2 mg, 58% yield, *E/Z* = 1:1. ¹H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 7.80–7.79 (m, 2H), 7.60–7.58 (m, 2H), 7.49–7.42 (m, 4H), 7.38–7.24 (m, 16H), 7.15–7.13 (m, 2H), 7.10–7.09 (m, 2H), 6.01 (s, 1H), 4.57 (d, *J* = 2.2 Hz, 2H), 4.42 (d, *J* = 3.8 Hz, 2H), 2.41 (s, 3H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.2, 165.3, 143.0, 141.8, 140.7, 139.0, 136.4, 136.3, 134.0, 131.1, 130.9, 129.6, 129.4, 128.9, 128.8, 128.8, 128.6, 128.2, 128.1, 128.0, 127.9, 127.7, 126.8, 126.5, 126.4, 126.4, 49.7, 46.6, 21.5, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C₂₁H₂₀N₂O₂S+Na⁺: 387.1138, Found: 387.1137; IR (neat, cm⁻¹): ν 3288, 1531, 1137, 1085, 686.




Ethyl (phenyl(tosylimino)methyl)glycinate (4g). Petroleum ether/ ethylacetate = 2.5:1, colorless liquid, 21.4 mg, 88% yield, *E/Z* = 1:3. ¹H NMR (400 MHz, CDCl₃) δ 8.96 (s, 0.33H), 7.91 (s, 0.65H), 7.63–7.61 (m, 2H), 7.52–7.46 (m, 2.68H), 7.40–7.37 (m, 2.68H), 7.30–7.28 (m, 0.67H), 7.17–7.15 (m, 2H), 6.23 (s, 1H), 4.23–4.17 (m, 4.67H), 3.98 (s, 0.66H), 2.42 (s, 1H), 2.37 (s, 3H), 1.28–1.25 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 168.8, 165.2, 142.0, 140.4, 133.5, 131.2, 131.1, 128.9, 128.7, 128.2,


127.9, 127.8, 126.7, 126.5, 61.9, 44.0, 30.9, 21.4, 14.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{18}H_{20}N_2O_4S+Na^+$: 383.1036, Found: 383.1029; IR (neat, cm^{-1}): ν 3304, 1741, 1530, 1139, 1086, 687.




Ethyl (1-(tosylimino)ethyl)glycinate (4h). Petroleum ether/ ethylacetate = 1:1, colorless liquid, 42.8 mg, 72% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.77–7.75 (m, 2H), 7.26–7.24 (m, 2H), 6.76 (s, 1H), 4.16 (q, $J = 7.1$ Hz, 2H), 4.02 (d, $J = 3.4$ Hz, 2H), 2.40 (s, 6H), 1.23 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 168.7, 165.9, 142.3, 140.0, 129.1, 126.2, 61.6, 43.4, 21.3, 20.5, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $C_{13}H_{18}N_2O_4S+Na^+$: 321.0879, Found: 321.0882; IR (neat, cm^{-1}): ν 3290, 1752, 1558, 1139, 1087, 669.




Methyl (1-(tosylimino)ethyl)-L-phenylalaninate (4i). Petroleum ether/ ethylacetate = 2:1, colorless liquid, 59.5 mg, 80% yield, $E/Z > 99:1$, $[\alpha]_D^{20} = 40.3$ (c 1, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.77–7.75 (m, 2H), 7.27–7.22 (m, 5H), 7.01–7.00 (m, 2H), 6.36 (d, $J = 6.0$ Hz, 1H), 4.83 (q, $J = 5.8$ Hz, 1H), 3.65 (s, 3H), 3.18–3.01 (m, 2H), 2.40 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 171.1, 165.0, 142.2, 140.1, 135.3, 129.1, 129.0, 128.5, 127.1, 126.2, 55.2, 52.4, 36.7, 21.4, 20.7. HRMS (ESI-TOF): Anal. Calcd. For $C_{19}H_{22}N_2O_4S+Na^+$: 397.1192, Found: 397.1184; IR (neat, cm^{-1}): ν 3294, 1742, 1540, 1272, 1141, 1089, 697.



***N*-(2-oxotetrahydrothiophen-3-yl)-*N'*-tosylacetimidamide (4j).** Petroleum ether/ethylacetate = 2:1, light yellow solid, 34.0 mg, 55% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, DMSO) δ 8.96 (d, *J* = 7.8 Hz, 1H), 7.67–7.65 (m, 2H), 7.34–7.32 (m, 2H), 4.86–4.79 (m, 1H), 3.47–3.40 (m, 1H), 3.32–3.28 (m, 1H), 2.53–2.47 (m, 1H), 2.36 (s, 3H), 2.24 (s, 3H), 2.14–2.06 (m, 1H). ¹³C NMR (101 MHz, DMSO) δ 204.1, 166.5, 141.8, 140.7, 129.3, 125.9, 59.8, 29.6, 27.0, 20.9, 19.9. HRMS (ESI-TOF): Anal. Calcd. For C₁₃H₁₆N₂O₃S₂+Na⁺: 335.0495, Found: 335.0497; IR (neat, cm⁻¹): ν 3269, 2918, 1697, 1537, 1262, 1086, 665.




***N*-methyl-*N'*-tosylformimidamide (4k).** Petroleum ether/ethylacetate = 1:1, white solid, 37.4 mg, 88% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, 1H), 7.73–7.71 (m, 2H), 7.26–7.24 (m, 2H), 7.16 (s, 1H), 2.89 (s, 3H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.6, 142.7, 139.0, 129.4, 126.2, 28.3, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C₉H₁₂N₂O₂S+Na⁺: 235.0512, Found: 235.0504; IR (neat, cm⁻¹): ν 3372, 1619, 1266, 1140, 906, 681.




4-Methyl-*N*-(pyrrolidin-2-ylidene)benzenesulfonamide (4l). Petroleum ether/ethylacetate = 1:1, white solid, 42.6 mg, 90% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 1H), 7.81–7.79 (m, 2H), 7.28–7.26 (m, 2H), 3.57 (t, *J* = 7.1 Hz, 2H), 2.70 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.08–2.01 (m, 2H). ¹³C NMR (101 MHz, CDCl₃)


δ 171.6, 142.6, 139.4, 129.2, 126.3, 46.2, 32.6, 21.4, 20.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{11}H_{14}N_2O_2S+Na^+$: 261.0668, Found: 261.0660; IR (neat, cm^{-1}): ν 3202, 1611, 1143, 809, 666.




4-Methyl-N-(piperidin-2-ylidene)benzenesulfonamide (4m). Petroleum ether/ethylacetate = 1.5:1, white solid, 35.1 mg, 70% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 8.68 (s, 1H), 7.81–7.79 (m, 2H), 7.28–7.26 (m, 2H), 3.38 (m, 2H), 2.49 (m, 2H), 2.40 (s, 3H), 1.75 (m, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.3, 142.4, 139.8, 129.2, 126.2, 42.3, 30.4, 21.4, 21.2, 19.1. HRMS (ESI-TOF): Anal. Calcd. For $C_{12}H_{16}N_2O_2S+Na^+$: 275.0825, Found: 275.0815; IR (neat, cm^{-1}): ν 3220, 1608, 1273, 1146, 676.




N-(azepan-2-ylidene)-4-methylbenzenesulfonamide (4n). Petroleum ether/ethylacetate = 2:1, white solid, 29.8 mg, 56% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 8.61 (s, 1H), 7.82–7.80 (m, 2H), 7.28–7.26 (m, 2H), 3.36 (m, 2H), 2.50–2.48 (m, 2H), 2.40 (s, 3H), 1.74–1.73 (m, 2H), 1.64 (m, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 171.8, 142.6, 139.4, 129.2, 126.2, 44.6, 36.6, 29.9, 28.5, 23.5, 21.4. HRMS (ESI-TOF): Anal. Calcd. For $C_{13}H_{18}N_2O_2S+Na^+$: 289.0981, Found: 289.0972; IR (neat, cm^{-1}): ν 3333, 2931, 1604, 1266, 892, 685.




***N*-(azocan-2-ylidene)-4-methylbenzenesulfonamide (4o).** Petroleum ether/ethylacetate = 3:1, white solid, 37.2 mg, 66% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.83–7.81 (m, 2H), 7.28–7.29 (m, 2H), 3.43–3.42 (m, 2H), 2.45–2.40 (m, 5H), 1.73 (m, 2H), 1.61 (m, 2H), 1.43–1.40 (m, 2H), 1.37–1.34 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 170.8, 142.6, 139.4, 129.1, 126.3, 42.8, 32.3, 31.5, 28.8, 25.2, 24.0, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C₁₄H₂₀N₂O₂S+Na⁺: 303.1138, Found: 303.1126; IR (neat, cm⁻¹): ν 2933, 1597, 1278, 1140, 612.




***N*-(3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (4p).** Petroleum ether/ethylacetate = 4.5:1, 37.9 mg, white solid, 63% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 10.17 (s, 1H), 7.88–7.86 (m, 2H), 7.30–7.28 (m, 2H), 7.23–7.20 (m, 1H), 7.15–7.14 (m, 1H), 7.08–7.04 (m, 1H), 6.91–6.89 (m, 1H), 2.90–2.86 (m, 2H), 2.73–2.72 (m, 2H), 2.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 143.2, 138.8, 134.8, 129.4, 128.2, 127.8, 126.4, 124.7, 124.2, 116.7, 30.4, 23.8, 21.5. HRMS (ESI-TOF): Anal. Calcd. For C₁₆H₁₆N₂O₂S+H⁺: 301.1005, Found: 301.1018; IR (neat, cm⁻¹): ν 3287, 1575, 1275, 1081, 757, 687.




4-Methyl-N-(2-azaspiro[4.5]decan-3-ylidene)benzenesulfonamide (4q). Petroleum ether/ ethylacetate = 3.5:1, white solid, 44.0 mg, 72% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.23 (s, 1H), 7.80–7.78 (d, *J* = 7.8 Hz, 2H), 7.28–7.26 (m, 2H), 3.29 (s, 2H), 2.54 (s, 2H), 2.40 (s, 3H), 1.45–1.41 (m, 10H). ¹³C NMR (101 MHz, CDCl₃) δ 170.7, 142.6, 139.5, 129.2, 126.3, 56.8, 45.1, 39.4, 36.1, 25.3, 22.8, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C₁₆H₂₂N₂O₂S+Na⁺: 329.1294, Found: 329.1282; IR (neat, cm⁻¹): ν 2919, 1609, 1150, 816, 667.




N-(pyrrolidin-2-ylidene)thiophene-2-sulfonamide (4r). Petroleum ether/ ethylacetate = 1:1, white solid, 45.2 mg, 98% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.614–7.606 (m, 1H), 7.53–7.52 (m, 1H), 7.05–7.03 (m, 1H), 3.60 (t, *J* = 6.7 Hz, 2H), 2.80–2.77 (m, 2H), 2.11–2.07 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 172.3, 143.6, 130.8, 130.6, 126.9, 46.2, 32.4, 20.0. HRMS (ESI-TOF): Anal. Calcd. For C₈H₁₀N₂O₂S₂+Na⁺: 253.0076, Found: 353.0078; IR (neat, cm⁻¹): ν 3100, 1607, 1300, 1139, 1013, 722, 664.



2-(Ethylsulfonyl)-N-(pyrrolidin-2-ylidene)imidazo[1,2-a]pyridine-3-sulfonamide (4s). Petroleum ether/ ethylacetate = 1:2, white solid, 41.1 mg, 58% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 8.92–8.90 (m, 1H), 7.87–7.85 (m, 1H), 7.58–7.54 (m, 1H), 7.21–7.18 (m, 1H), 3.75–3.66 (m, 4H), 2.69 (t, *J* = 8.1 Hz, 2H), 2.11–2.03 (m, 2H), 1.40 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.4, 144.3, 143.7, 129.1, 128.0, 122.6, 118.9, 116.1, 50.3, 47.8, 34.3, 19.4, 6.8. HRMS (ESI-TOF): Anal. Calcd. For C₁₃H₁₆N₄O₄S₂+H⁺: 357.0686, Found: 357.0697; IR (neat, cm⁻¹): ν 3305, 1609, 1302, 1133, 729.




N-(pyrrolidin-2-ylidene)naphthalene-2-sulfonamide (4t). Petroleum ether/ ethylacetate = 1.5:1, white solid, 41.5 mg, 76% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 8.40 (s, 1H), 7.95–7.91 (m, 3H), 7.88–7.86 (m, 1H), 7.61–7.54 (m, 2H), 3.55 (m, 2H), 2.72–2.71 (m, 2H), 2.04–2.02 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 171.8, 139.2, 134.5, 132.0, 129.1, 129.0, 128.2, 127.7, 127.1, 126.9, 122.4, 46.3, 32.7, 19.9. HRMS (ESI-TOF): Anal. Calcd. For C₁₄H₁₄N₂O₂S+Na⁺: 297.0668, Found: 297.0671; IR (neat, cm⁻¹): ν 2969, 1612, 1125, 818, 641.




1-Phenyl-N-(pyrrolidin-2-ylidene)methanesulfonamide (4u). Petroleum ether/ ethylacetate = 1:1, white solid, 34.8 mg, 73% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 1H), 7.43–7.41 (m, 2H), 7.35–7.34 (m, 3H), 4.25 (s, 2H), 3.24 (t, *J* = 6.1 Hz, 2H), 2.51–2.47 (m, 2H), 1.86 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 172.3, 130.9, 129.9, 128.2, 128.2, 59.9, 46.1, 32.7, 19.6. HRMS (ESI-TOF): Anal. Calcd.

For $C_{11}H_{14}N_2O_2S+Na^+$: 261.0668, Found: 261.0675; IR (neat, cm^{-1}): ν 3107, 1618, 1302, 1126, 699.




Methyl (1-((methylsulfonyl)imino)ethyl)-L-phenylalaninate (4v). Petroleum ether/ethylacetate = 1.5:1, colourless liquid, 58.2 mg, 97% yield, E/Z = 3:1, $[\alpha]_D^{20}$ = 125.9 (c 1, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.31–7.24 (m, 4H), 7.11–7.09 (d, J = 7.6 Hz, 2.67H), 6.39–6.37 (m, 1H), 6.18–6.17 (m, 0.33H), 4.86–4.81 (m, 1.33H), 3.73 (s, 3H), 3.71 (s, 1H), 3.23–3.05 (m, 2.67H), 2.95 (s, 3.41H), 2.40 (s, 3H), 1.97 (s, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 172.0, 171.2, 169.8, 164.6, 135.7, 135.3, 129.1, 129.0, 128.5, 128.4, 127.2, 127.0, 55.1, 53.1, 52.4, 52.2, 42.8, 37.7, 36.9, 22.9, 20.7. HRMS (ESI-TOF): Anal. Calcd. For $C_{13}H_{18}N_2O_4S+Na^+$: 321.0879, Found: 321.0887; IR (neat, cm^{-1}): ν 3301, 1741, 1543, 1267, 1112, 789.




Methyl (1-((cyclopropylsulfonyl)imino)ethyl)-L-phenylalaninate (4w). Petroleum ether/ethylacetate = 2:1, colourless liquid, 60.4 mg, 93% yield, E/Z = 2.2:1, $[\alpha]_D^{20}$ = 114.9 (c 1, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.31–7.22 (m, 4.39H), 7.12–7.10 (m, 2.9H), 6.38 (d, J = 6.3 Hz, 1H), 6.19 (d, J = 6.8 Hz, 0.45H), 4.88–4.81 (m, 1.46H), 3.73 (s, 3H), 3.71 (s, 1.35H), 3.24–3.19 (m, 0.91H), 3.16–3.04 (m, 2H), 2.54–2.49 (m, 1.45H), 2.40 (s, 3H), 1.97 (s, 1.45H), 1.16–1.12 (m, 2.91H), 1.01–0.99 (m, 0.9H), 0.95–0.93 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 172.0, 171.3, 169.8, 164.6, 135.7, 135.4, 129.1, 129.0, 128.5, 128.4, 127.1, 127.0, 55.2, 53.1, 52.4, 52.2, 37.7, 36.8, 32.2, 32.1, 22.9, 20.8, 5.8, 5.13, 5.08. HRMS (ESI-TOF): Anal. Calcd. For


$C_{15}H_{20}N_2O_4S+Na^+$: 347.1036, Found: 347.1026; IR (neat, cm^{-1}): ν 3305, 1741, 1542, 1113, 731, 699.




***p*-tolyl pyrrolidin-2-ylidenesulfamate (4x).** Petroleum ether/ ethylacetate = 2:1, white solid, 32.9 mg, 63% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 8.26 (s, 1H), 7.27–7.13 (m, 4H), 3.50–3.49 (m, 2H), 2.79–2.76 (m, 2H), 2.33 (s, 3H), 2.07 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 174.2, 148.3, 136.2, 129.9, 121.8, 46.3, 32.3, 20.8, 20.3. HRMS (ESI-TOF): Anal. Calcd. For $C_{11}H_{14}N_2O_3S+Na^+$: 277.0617, Found: 277.0613; IR (neat, cm^{-1}): ν 3104, 1629, 1349, 1154, 821.




Methyl (1-((*N,N*-dimethylsulfamoyl)imino)ethyl)-*L*-phenylalaninate (4y). Petroleum ether/ ethylacetate = 2:1, white solid, 51.1 mg, 78% yield, $E/Z > 99:1$, $[\alpha]_D^{20} = 41.1$ (c 1, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.32–7.24 (m, 3H), 7.12–7.10 (m, 2H), 6.12 (d, $J = 6.0$ Hz, 1H), 4.81–4.76 (m, 1H), 3.73 (s, 3H), 3.26–3.21 (m, 1H), 3.13–3.08 (m, 1H), 2.74 (s, 6H), 2.38 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 171.3, 165.7, 135.3, 129.0, 128.7, 127.3, 55.2, 52.4, 38.8, 38.2, 36.7, 20.6. HRMS (ESI-TOF): Anal. Calcd. For $C_{14}H_{21}N_3O_4S+Na^+$: 350.1145, Found: 350.1150; IR (neat, cm^{-1}): ν 3316, 1748, 1541, 1145, 716.




Ethyl *N*-phenyl-*N*-(1-(tosylimino)ethyl)glycinate (5a). Petroleum ether/ ethylacetate = 4:1, light yellow solid, 60.2 mg, 80% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.83–7.81 (m, 2H), 7.47–7.37 (m, 3H), 7.33–7.31 (m, 2H), 7.28–7.26 (m, 2H), 4.37 (s, 2H), 4.06 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 2.32 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.8, 166.2, 142.2, 142.1, 140.4, 130.0, 128.9, 128.9, 127.5, 126.2, 61.2, 53.8, 21.3, 19.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 397.1192, Found: 397.1196; IR (neat, cm^{-1}): ν 3332, 2974, 1742, 1536, 1084, 687.



Ethyl *N*-(1-(tosylimino)ethyl)-*N*-(4-(trifluoromethyl)phenyl)glycinate (5b). Petroleum ether/ ethylacetate = 4:1, colourless liquid, 49.4 mg, 56% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.80 (m, 2H), 7.69–7.68 (m, 1H), 7.63–7.62 (m, 2H), 7.59–7.55 (m, 1H), 7.29–7.27 (m, 2H), 4.37 (s, 2H), 4.07 (q, J = 7.1 Hz, 2H), 2.42 (s, 3H), 2.34 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 166.0, 142.8, 142.4, 140.1, 131.4, 130.8, 129.1, 126.3, 125.8 (q, J = 3.3 Hz), 124.8 (q, J = 3.7 Hz), 61.5, 53.8, 21.4, 19.2, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_4\text{S}+\text{H}^+$: 443.1247, Found: 443.1258; IR (neat, cm^{-1}): ν 2985, 1743, 1543, 1086, 838.




Ethyl N-benzyl-N-(1-(tosylimino)ethyl)glycinate (5c). Petroleum ether/ ethylacetate = 3:1, colourless liquid, 27.8 mg, 36% yield, $E/Z = 3:1$. ^1H NMR (400 MHz, CDCl_3) δ 7.81–7.77 (m, 2.67H), 7.40–7.28 (m, 4H), 7.25–7.23 (m, 2.69H), 7.21–7.17 (m, 2.67H), 4.75 (s, 1H), 4.69 (s, 2H), 4.16 (q, $J = 7.1$ Hz, 0.67H), 4.08 (s, 7H), 4.04 (q, $J = 7.1$ Hz, 2H), 4.00 (s, 0.66H), 2.61 (s, 3H), 2.53 (s, 1H), 2.40 (s, 4H), 1.23 (t, $J = 7.1$ Hz, 1H), 1.14 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 167.7, 166.7, 166.6, 142.0, 140.6, 135.1, 134.5, 129.1, 129.1, 129.0, 128.9, 128.7, 128.5, 128.2, 128.0, 126.6, 126.6, 126.2, 126.2, 62.0, 61.3, 53.7, 52.8, 50.4, 49.7, 21.4, 21.2, 18.0, 17.7, 14.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}_4\text{S} + \text{H}^+$: 411.1349, Found: 411.1347; IR (neat, cm^{-1}): ν 2981, 1741, 1541, 1143, 686.




Ethyl N-benzyl-N-(phenyl(tosylimino)methyl)glycinate (5d). Petroleum ether/ ethylacetate = 3.5:1, colourless liquid, 50.9 mg, 57% yield, $E/Z = 3:1$. ^1H NMR (400 MHz, CDCl_3) δ 7.80–7.78 (m, 0.66H), 7.52–7.50 (m, 2H), 7.44–7.26 (m, 10.66H), 7.19–7.08 (m, 5.22H), 4.92 (s, 0.66H), 4.34 (s, 2H), 4.26–4.20 (q, $J = 7.2$ Hz, 1H), 4.16 (s, 2H), 4.10 (q, $J = 7.2$ Hz, 2H), 3.66 (s, 0.73H), 2.40 (s, 1H), 2.36 (s, 3H), 1.22 (t, $J = 7.1$ Hz, 3H), 1.16 (t, $J = 7.1$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 167.8, 167.5, 167.3, 143.2, 141.8, 140.3, 139.3, 135.0, 134.6, 131.4, 131.2, 130.1, 130.0, 129.5, 128.9, 128.8, 128.7, 128.5, 128.3, 128.2, 128.0, 127.3, 127.2, 127.1, 126.45, 126.41, 126.3, 61.7, 61.4, 54.1, 51.7, 50.0, 48.5, 21.4, 21.3, 13.97, 13.95.

HRMS (ESI-TOF): Anal. Calcd. For $C_{25}H_{26}N_2O_4S+H^+$: 451.1686, Found: 451.1681;
IR (neat, cm^{-1}): ν 2981, 1740, 1522, 1143, 684.




Diethyl 2,2'-((phenyl(tosylimino)methyl)azanediyl)diacetate (5e). Petroleum ether/ethylacetate = 2.5:1, light yellow solid, 55.2 mg, 62% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.51–7.49 (m, 2H), 7.46–7.42 (m, 1H), 7.37–7.34 (m, 2H), 7.20–07.18 (m, 2H), 7.14–7.12 (m, 2H), 4.35 (s, 2H), 4.19–4.09 (m, 4H), 3.87 (s, 2H), 2.36 (s, 3H), 1.25 (t, $J = 7.1$ Hz, 3H), 1.19 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.9, 167.7, 167.3, 141.9, 140.1, 130.7, 130.3, 128.7, 128.3, 127.1, 126.4, 61.7, 61.4, 51.9, 50.1, 21.3, 14.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $C_{22}H_{26}N_2O_6S+Na^+$: 469.1404, Found: 469.1414; IR (neat, cm^{-1}): ν 2985, 1741, 1540, 1145, 679.




Diethyl 2,2'-((1-(tosylimino)ethyl)azanediyl)diacetate (5f). Petroleum ether/ethylacetate = 1.5:1, colourless liquid, 42.7 mg, 56% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.76–7.74 (m, 2H), 7.25–7.23 (m, 2H), 4.25–4.18 (m, 6H), 4.06 (q, $J = 7.1$ Hz, 2H), 2.51 (s, 3H), 2.39 (s, 3H), 1.28 (t, $J = 7.1$ Hz, 3H), 1.16 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.9, 167.6, 166.6, 142.1, 140.3, 129.0, 126.2, 62.1, 61.3, 51.6, 51.2, 21.3, 17.4, 14.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For

C₁₇H₂₄N₂O₆S+Na⁺: 407.1247, Found: 407.1248; IR (neat, cm⁻¹): ν 2978, 1745, 1551, 1209, 684.




Ethyl *N*-phenyl-*N*-((tosylimino)methyl)glycinate (5g). Petroleum ether/ ethylacetate = 5:1, colourless liquid, 55.6 mg, 77% yield, *E/Z* = 2.8:1. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 7.78–7.73 (m, 2.73H), 7.45–7.41 (m, 2H), 7.36–7.32 (m, 1H), 7.31–7.23 (m, 5.44H), 5.34 (d, *J* = 15.3 Hz, 0H), 4.57 (s, 2H), 4.11–4.04 (m, 2.72H), 3.76 (s, 1H), 2.41 (s, 1H), 2.40 (s, 3H), 1.17 (t, *J* = 7.2 Hz, 1H), 1.13 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 167.0, 158.7, 143.6, 142.8, 142.2, 138.4, 136.1, 129.8, 129.6, 129.2, 128.8, 127.7, 127.1, 126.5, 123.0, 119.7, 61.7, 50.7, 44.1, 21.4, 21.4, 13.83, 13.77. HRMS (ESI-TOF): Anal. Calcd. For C₁₈H₂₀N₂O₄S+H⁺: 361.1217, Found: 367.1218; IR (neat, cm⁻¹): ν 2981, 1743, 1575, 1147, 675.




Ethyl *N*-methyl-*N*-((tosylimino)methyl)glycinate (5h). Petroleum ether/ ethylacetate = 1.5:1, light yellow liquid, 29.7 mg, 50% yield, *E/Z* = 1.8:1. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 1H), 8.18 (s, 0.56H), 7.78–7.76 (m, 1.12H), 7.74–7.72 (m, 2H), 7.28–7.23 (m, 3.12H), 4.23 (q, *J* = 7.1 Hz, 1.28H), 4.17 (s, 2H), 4.14 (q, *J* = 7.1 Hz, 2H), 4.07 (s, 1.12H), 3.20 (s, 3H), 3.05 (s, 1.68H), 2.40 (s, 1.68H), 2.39 (s, 3H), 1.29 (t, *J* = 7.1 Hz, 1.79H), 1.20 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.6, 166.9, 160.2, 159.9, 142.6, 142.5, 139.0, 138.9, 129.3, 129.2, 126.5, 126.4,

762.0, 61.6, 55.1, 49.1, 40.3, 35.0, 29.6, 21.4, 14.03, 13.92. HRMS (ESI-TOF): Anal. Calcd. For $C_{13}H_{18}N_2O_4S+H^+$: 299.1060, Found: 299.1062; IR (neat, cm^{-1}): ν 2923, 1742, 1608, 1144, 1083, 671.




Ethyl ((tosylimino)methyl)glycinate (5i). Petroleum ether/ ethylacetate = 4:1, white solid, 29.0 mg, 51% yield, $E/Z = 1:5.9$. 1H NMR (400 MHz, $CDCl_3$) δ 9.11 (s, 0.17H), 7.78–7.73 (m, 2.34H), 7.40–7.38 (m, 0.34H), 7.32–7.30 (m, 2H), 5.20 (s, 1H), 4.35 (s, 0.17H), 4.27–4.21 (m, 1H), 4.08 (q, $J = 7.1$ Hz, 2H), 3.88 (q, $J = 7.1$ Hz, 0.34H), 3.77 (d, $J = 3.0$ Hz, 2H), 2.47 (s, 0.34H), 2.42 (s, 3H), 2.41 (s, 0.5H), 1.18 (t, $J = 7.1$ Hz, 3H), 0.96 (t, $J = 7.1$ Hz, 0.51H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 168.7, 156.5, 143.7, 136.1, 130.4, 129.7, 129.5, 127.9, 127.2, 127.1, 61.8, 61.6, 45.6, 44.1, 21.7, 21.5, 13.9, 13.6. HRMS (ESI-TOF): Anal. Calcd. For $C_{12}H_{16}N_2O_4S+Na^+$: 307.0723, Found: 307.0728; IR (neat, cm^{-1}): ν 3221, 1732, 1331, 1154, 659.




Methyl (2Z)-2-(N-(2-ethoxy-2-oxoethyl)-N'-tosylacetimidamido)-3-phenylacrylate (5j). Petroleum ether/ ethylacetate = 10:1, colourless liquid, 45.1 mg, 50% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.85–7.83 (m, 2H), 7.76 (s, 1H), 7.68–7.67 (m, 2H), 7.48–7.40 (m, 3H), 7.29–7.27 (m, 2H), 4.12 (d, $J = 2.8$ Hz, 2H), 4.00–3.90 (m, 2H), 3.87 (s, 3H), 2.42 (s, 3H), 2.38 (s, 3H), 1.10 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.5, 167.1, 164.5, 142.3, 140.0, 139.1, 131.6, 131.0, 130.8, 129.2, 129.0, 128.9, 126.4, 61.1, 53.0, 52.6, 21.4, 18.0, 13.8. HRMS (ESI-TOF): Anal. Calcd.


For $C_{23}H_{26}N_2O_6S+Na^+$: 481.1404, Found: 481.1403; IR (neat, cm^{-1}): ν 2981, 1717, 1550, 1147, 683.




Ethyl 2-(2-(tosylimino)pyrrolidin-1-yl)acetate (5k). Petroleum ether/ ethylacetate = 1.5:1, white solid, 49.9 mg, 77% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.76–7.74 (m, 2H), 7.25–7.23 (m, 2H), 4.18–4.12 (m, 4H), 3.54 (t, $J = 7.1$ Hz, 2H), 3.03 (t, $J = 7.9$ Hz, 2H), 2.39 (s, 3H), 2.12–2.05 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 170.9, 167.1, 142.0, 140.0, 128.9, 126.2, 61.3, 50.0, 45.8, 30.2, 21.2, 19.1, 13.8. HRMS (ESI-TOF): Anal. Calcd. For $C_{15}H_{20}N_2O_4S+Na^+$: 347.1036, Found: 347.1028; IR (neat, cm^{-1}): ν 2972, 1745, 1567, 1144, 670.




Ethyl 2-(1-(tosylimino)isoindolin-2-yl)acetate (5l). Petroleum ether/ ethylacetate = 2:1, light yellow liquid, 31.2 mg, 42% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 8.90–8.88 (m, 1H), 7.90–7.88 (m, 2H), 7.60–7.56 (m, 1H), 7.54–7.50 (m, 1H), 7.46–7.45 (m, 1H), 7.27–7.25 (m, 2H), 4.66 (s, 2H), 4.38 (s, 2H), 4.16 (q, $J = 7.1$ Hz, 2H), 2.40 (s, 3H), 1.22 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.8, 162.8, 142.1, 141.9, 141.0, 132.2, 129.3, 129.1, 129.0, 128.4, 126.2, 122.3, 61.6, 53.6, 46.2, 21.4, 14.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{19}H_{20}N_2O_4S+Na^+$: 395.1036, Found: 395.1044; IR (neat, cm^{-1}): ν 2957, 1747, 1562, 914, 684.



Ethyl 2-(3-(tosylimino)-2-azaspiro[4.5]decan-2-yl)acetate (5m). Petroleum ether/ethylacetate = 3.5:1, white solid, 70.5 mg, 90% yield, *E/Z* = 4.5:1. ^1H NMR (400 MHz, CDCl_3) δ 7.81–7.74 (m, 2.39H), 7.31–7.23 (m, 2.42H), 4.17–4.12 (m, 4.88H), 4.03 (s, 0.44H), 3.30 (s, 2H), 3.24 (s, 0.45H), 2.89 (s, 2H), 2.39 (s, 3H), 2.29 (s, 0.66H), 1.54–1.40 (m, 12.26H), 1.29 (t, J = 7.1 Hz, 0.48H), 1.23 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.5, 170.1, 168.5, 167.3, 141.9, 140.2, 128.9, 126.2, 61.4, 61.1, 60.6, 45.6, 43.7, 42.9, 38.5, 36.6, 36.3, 36.0, 25.4, 25.2, 22.6, 21.2, 14.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_4\text{S}+\text{H}^+$: 393.1843, Found: 393.1842; IR (neat, cm^{-1}): ν 2921, 1748, 1572, 1144, 670.




Ethyl N-phenyl-N-(1-((thiophen-2-ylsulfonyl)imino)ethyl)glycinate (5n). Petroleum ether/ethylacetate = 4:1, colourless liquid, 50.7 mg, 69% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.63–7.62 (m, 1H), 7.52–7.51 (m, 1H), 7.46–7.40 (m, 3H), 7.34–7.29 (m, 2H), 7.05–7.02 (m, 1H), 4.44 (s, 2H), 4.14 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.6, 166.6, 144.7, 142.0, 130.4, 130.0, 130.0, 129.0, 127.4, 126.6, 61.4, 53.9, 19.1, 14.0. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_4\text{S}_2+\text{Na}^+$: 389.0600, Found: 389.0609; IR (neat, cm^{-1}): ν 2982, 1745, 1540, 1145, 786.




Ethyl *N*-(1-((naphthalen-2-ylsulfonyl)imino)ethyl)-*N*-phenylglycinate (5o).


Petroleum ether/ ethylacetate = 4:1, white solid, 52.3 mg, 64% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 7.97–7.88 (m, 4H), 7.6–7.56 (m, 2H), 7.46–7.39 (m, 3H), 7.33–7.31 (m, 2H), 4.38 (s, 2H), 3.99 (q, *J* = 7.1 Hz, 2H), 2.37 (s, 3H), 1.04 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 166.4, 142.2, 140.2, 134.4, 132.0, 130.0, 129.1, 129.0, 128.6, 128.1, 127.7, 127.5, 127.0, 126.6, 122.6, 61.3, 54.0, 19.2, 13.8. HRMS (ESI-TOF): Anal. Calcd. For C₂₂H₂₂N₂O₄S+H⁺: 411.1373, Found: 411.1361; IR (neat, cm⁻¹): ν 2981, 1742, 1537, 1073, 677.




Ethyl *N*-(1-((benzylsulfonyl)imino)ethyl)-*N*-phenylglycinate (5p). Petroleum ether/ ethylacetate = 4:1, colourless liquid, 50.0 mg, 67% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 7.49–7.47 (m, 2H), 7.45–7.35 (m, 6H), 7.27–7.25 (m, 2H), 4.34 (s, 2H), 4.28 (s, 2H), 4.23 (q, *J* = 7.1 Hz, 2H), 2.11 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 166.9, 142.1, 131.0, 130.3, 130.0, 128.9, 128.3, 128.1, 127.5, 61.4, 60.8, 53.6, 19.1, 14.1. HRMS (ESI-TOF): Anal. Calcd. For C₁₉H₂₂N₂O₄S+H⁺: 397.1192, Found: 397.1200; IR (neat, cm⁻¹): ν 2978, 1738, 1544, 1100, 696.




Ethyl *N*-(1-((methylsulfonyl)imino)ethyl)-*N*-phenylglycinate (5q). Petroleum ether/ethylacetate = 3:1, white solid, 37.4 mg, 63% yield, *E/Z* = 3.3:1. ^1H NMR (400 MHz, CDCl_3) δ 7.76–7.74 (m, 2H), 7.25–7.23 (m, 2H), 4.24–4.18 (m, 6H), 4.06 (q, J = 7.1 Hz, 2H), 2.51 (s, 3H), 2.39 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.9, 167.6, 166.6, 142.1, 140.3, 129.0, 126.2, 62.1, 61.3, 51.6, 51.2, 21.3, 17.4, 14.0, 13.9. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 321.0879, Found: 321.0890; IR (neat, cm^{-1}): ν 3287, 1736, 1550, 1104, 801.




Ethyl *N*-(1-((cyclopropylsulfonyl)imino)ethyl)-*N*-phenylglycinate (5r). Petroleum ether/ethylacetate = 3.5:1, colourless liquid, 44.3 mg, 68% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.48–7.39 (m, 3H), 7.34–7.32 (m, 2H), 4.40 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 2.60–2.54 (m, 1H), 2.31 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H), 1.20–1.16 (m, 2H), 0.98–0.93 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 165.9, 142.3, 130.0, 128.8, 127.5, 61.3, 53.8, 32.3, 19.3, 14.1, 5.3, 5.1. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_4\text{S}+\text{H}^+$: 325.1217, Found: 325.1228; IR (neat, cm^{-1}): ν 2983, 1743, 1546, 1132, 699.




Ethyl *N*-phenyl-*N*-(1-((*p*-tolylloxy)sulfonyl)imino)ethylglycinate (5s). Petroleum ether/ ethylacetate = 7:1, colourless liquid, 52.5 mg, 67% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.48–7.40 (m, 3H), 7.33–7.31 (m, 1H), 7.25–7.22 (m, 2H), 7.20–7.16 (m, 3H), 4.41 (s, 2H), 4.17 (q, J = 7.1 Hz, 2H), 2.35 (s, 3H), 2.27 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.6, 167.5, 148.7, 142.0, 136.1, 130.2, 129.8, 129.2, 127.3, 121.9, 61.7, 53.8, 20.8, 19.0, 14.0. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_5\text{S}+\text{Na}^+$: 413.1142, Found: 413.1144; IR (neat, cm^{-1}): ν 2985, 1744, 1501, 1147, 790.




Isopropyl *N*-phenyl-*N*-(1-(tosylimino)ethyl)glycinate (5t). Petroleum ether/ ethylacetate = 4.5:1, light yellow solid, 52.5 mg, 68% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.83–7.81 (m, 2H), 7.46–7.39 (m, 3H), 7.33–7.31 (m, 2H), 7.27–7.25 (m, 2H), 4.97–4.89 (m, 1H), 4.35 (s, 2H), 2.40 (s, 3H), 2.33 (s, 3H), 1.15 (s, 3H), 1.13 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.2, 166.2, 142.2, 142.0, 140.4, 129.9, 128.9, 128.8, 127.4, 126.2, 69.1, 54.0, 21.5, 21.3, 19.1. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}_4\text{S}+\text{H}^+$: 389.1530, Found: 389.1544; IR (neat, cm^{-1}): ν 2979, 1745, 1540, 1082, 683.



Cyclohexyl *N*-phenyl-*N*-(1-(tosylimino)ethyl)glycinate (5u). Petroleum ether/ethylacetate = 4.5:1, yellow liquid, 49.4 mg, 58% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.83–7.81 (m, 2H), 7.46–7.37 (m, 3H), 7.33–7.31 (m, 2H), 7.27–7.25 (m, 2H), 4.69–4.65 (m, 1H), 4.35 (s, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.69–1.65 (m, 4H), 1.53–1.51 (m, 1H), 1.31–1.26 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.2, 166.1, 142.3, 142.0, 140.4, 129.9, 128.9, 128.8, 127.4, 126.2, 74.0, 54.0, 31.2, 25.0, 23.5, 21.3, 19.1. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 451.1662, Found: 461.1669; IR (neat, cm^{-1}): ν 2937, 1739, 1544, 1089, 684.




Benzyl *N*-phenyl-*N*-(1-(tosylimino)ethyl)glycinate (5v). Petroleum ether/ethylacetate = 4.5:1, yellow liquid, 50.1 mg, 57% yield, *E/Z* > 99:1. ^1H NMR (400 MHz, CDCl_3) δ 7.80–7.78 (m, 2H), 7.43–7.37 (m, 2H), 7.34–7.32 (m, 4H), 7.29–7.27 (m, 2H), 7.25–7.23 (m, 2H), 7.21–7.19 (m, 2H), 5.01 (s, 2H), 4.42 (s, 2H), 2.37 (s, 3H), 2.32 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 166.3, 142.1, 140.3, 134.9, 130.0, 129.0, 128.9, 128.4, 128.3, 128.0, 127.4, 126.2, 67.0, 53.8, 21.3, 19.0. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_4\text{S}+\text{H}^+$: 437.1530, Found: 437.1520; IR (neat, cm^{-1}): ν 3062, 1749, 1548, 1088, 700.



2-(Naphthalen-1-yl)ethyl N-phenyl-N-(1-(tosylimino)ethyl)glycinate (5w).

Petroleum ether/ ethylacetate = 4:1, colourless liquid, 74.9 mg, 75% yield, *E/Z* = 4:1.


^1H NMR (400 MHz, CDCl_3) δ 8.06–8.04 (m, 0.25H), 7.99–7.97 (m, 1H), 7.87–7.79 (m, 4H), 7.76–7.74 (m, 1H), 7.54–7.45 (m, 2.57H), 7.40–7.32 (m, 6.51H), 7.2–7.26 (m, 1H), 7.24–7.14 (m, 4H), 5.00 (s, 0.5H), 4.48 (*J* = 7.2 Hz, 0.52H), 4.36 (*J* = 13.6, 6.1 Hz, 4.31 (m, 4H), 3.42 (t, *J* = 7.4 Hz, 0.51H), 3.22 (t, *J* = 7.4 Hz, 2H), 2.39 (s, 0.75H), 2.32 (s, 3H), 2.24 (s, 3H), 1.90 (s, 0.75H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.9, 169.1, 167.9, 166.3, 142.2, 142.2, 140.4, 133.8, 133.2, 131.9, 130.0, 129.7, 129.6, 129.1, 128.9, 128.8, 128.7, 128.2, 127.8, 127.4, 127.0, 127.0, 126.4, 126.3, 126.21, 126.16, 125.65, 125.60, 125.5, 125.4, 123.45, 123.40, 65.1, 54.0, 51.2, 32.0, 31.8, 22.1, 21.4, 21.3, 19.1. HRMS (ESI-TOF): Anal. Calcd. For $\text{C}_{29}\text{H}_{28}\text{N}_2\text{O}_4\text{S}+\text{Na}^+$: 523.1662, Found: 523.1649; IR (neat, cm^{-1}): ν 2924, 1742, 1539, 1086, 776.




2-(Thiophen-2-yl)ethyl N-phenyl-N-(1-(tosylimino)ethyl)glycinate (5x).

Petroleum ether/ ethylacetate = 4.5:1, light yellow liquid, 58.6 mg, 64% yield, *E/Z* = 2:1. ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.80 (m, 2H), 7.43–7.32 (m, 4H), 7.28–7.25 (m, 3H), 7.23–7.20 (m, 3H), 7.15–7.13 (m, 3H), 6.93–6.91 (m, 1.5H), 6.84–6.70 (m, 1.5H), 4.37–4.34 (m, 4H), 4.20 (t, *J* = 6.8 Hz, 2H), 3.16 (t, *J* = 6.8 Hz, 1H), 2.99 (t, *J* = 6.8 Hz, 2H), 2.36 (s, 3H), 2.31 (s, 3.64H), 1.91 (s, 1.51H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.8, 168.9, 167.6, 166.2, 143.1, 142.1, 142.1, 140.3, 139.5, 139.3, 130.0, 129.6,

129.0, 128.8, 128.1, 127.7, 127.4, 126.8, 126.8, 126.2, 125.49, 125.48, 123.93, 123.90, 65.18, 65.16, 53.9, 51.1, 29.0, 28.9, 22.0, 21.3, 19.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{23}H_{24}N_2O_4S_2+Na^+$: 479.1070, Found: 479.1072; IR (neat, cm^{-1}): ν 2955, 1743, 1540, 1147, 698.




Dut-3-en-1-yl N-phenyl-N-(1-(tosylimino)ethyl)glycinate (5y). Petroleum ether/ethylacetate = 4.5:1, yellow liquid, 39.0 mg, 49% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 7.83–7.81 (m, 2H), 7.46–7.38 (m, 3H), 7.32–7.26 (m, 4H), 5.74–7.64 (m, 1H), 5.08–5.05 (m, 2H), 4.37 (s, 2H), 4.04 (t, $J = 6.8$ Hz, 2H), 2.41 (s, 3H), 2.32 (s, 3H), 2.26 (q, $J = 6.7$ Hz, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.8, 166.2, 142.2, 142.1, 140.4, 133.5, 130.0, 129.0, 128.9, 127.5, 126.2, 117.3, 64.2, 53.8, 32.7, 21.4, 19.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{21}H_{24}N_2O_4S+Na^+$: 423.1349, Found: 423.1355; IR (neat, cm^{-1}): ν 2919, 1747, 1544, 1149, 1089, 702.




N-(4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (6a). Petroleum ether/ethylacetate = 2.5:1, light yellow liquid, 52.5 mg, 61% yield, $E/Z > 99:1$. 1H NMR (400 MHz, $CDCl_3$) δ 8.31 (s, 1H), 7.83–7.81 (m, 2H), 7.28–7.26 (m, 2H), 6.80–6.77 (m, 1H), 6.68–6.67 (m, 2H), 4.72–4.70 (m, 1H), 3.97–3.90 (m, 1H), 3.81 (s, 3H), 3.57–3.50 (m, 2H), 3.13–3.08 (m, 1H), 2.86–2.79 (m, 1H), 2.40 (s, 3H), 1.91–1.79 (m, 6H), 1.63–1.56 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 171.0, 149.2, 147.8, 142.7, 139.3, 133.0, 129.3, 126.4, 118.7, 113.5, 112.1, 80.4, 60.3, 56.0, 39.2, 32.7, 23.9, 21.4, 14.1. HRMS (ESI-TOF): Anal. Calcd. For $C_{23}H_{28}N_2O_4S$


+H⁺: 429.1843, Found: 429.1831; IR (neat, cm⁻¹): ν 2954, 1599, 1256, 1137, 810, 666.



(S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)-N'-tosylacetimidamide (6b). Petroleum ether/ ethylacetate = 1:3, white solid, 31.1 mg, 32% yield, *E/Z* > 99:1, $[\alpha]_{\text{D}}^{20} = 454.8$ (*c* 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.77–7.75 (m, 2H), 7.33–7.29 (m, 2H), 7.26–7.24 (m, 2H), 7.00–6.98 (m, 1H), 6.92–6.88 (m, 1H), 4.812–8.809 (m, 1H), 3.99–3.97 (m, 1H), 3.88–3.86 (m, 4H), 3.77–3.64 (m, 3H), 3.05 (m, 4H), 2.40 (s, 3H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.4, 154.5, 142.6, 140.0, 129.3, 126.4, 118.9, 114.1, 107.7, 107.5, 71.0, 66.8, 60.4, 51.0, 47.9, 44.1, 21.4, 20.6, 14.1. HRMS (ESI-TOF): Anal. Calcd. For C₂₃H₂₇FN₄O₅S+H⁺: 491.1759, Found: 491.1747; IR (neat, cm⁻¹): ν 3288, 1749, 1514, 1085, 661.




Ethyl (S)-5-(tosylimino)pyrrolidine-2-carboxylate (6c). Petroleum ether/ ethylacetate = 1.5:1, colourless liquid, 38.7 mg, 63% yield, *E/Z* > 99:1, $[\alpha]_{\text{D}}^{20} = 35.4$ (*c* 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 7.83–7.80 (m, 2H), 7.28–7.26 (m, 2H), 4.47–4.44 (m, 1H), 4.21 (q, *J* = 7.1 Hz, 2H), 2.76–2.73 (m, 2H), 2.45–2.36 (m, 4H), 2.18–2.09 (m, 1H), 1.29 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 177.8, 170.7, 142.8, 139.0, 129.2, 126.4, 61.9, 59.3, 31.3, 29.5, 21.4, 14.0. HRMS (ESI-TOF): Anal. Calcd. For C₁₄H₁₈N₂O₄S+Na⁺: 333.0879, Found: 333.0872; IR (neat, cm⁻¹): ν 3365, 2922, 1737, 1594, 1139, 810.



Methyl


(1-((((((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methoxy)sulfonyl)imino)ethyl)-L-phenylalaninate (6d).

Petroleum ether/ ethylacetate = 2:1, colourless liquid, 41.5 mg, 48% yield, *E/Z* > 99:1, $[\alpha]_D^{20} = 411.1$ (*c* 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.32–7.24 (m, 3H), 7.06–7.05 (m, 2H), 6.21 (d, *J* = 6.0 Hz, 1H), 4.94–4.92 (m, 1H), 4.64–4.61 (dd, *J* = 7.8, 2.6 Hz, 1H), 4.45 (d, *J* = 2.6 Hz, 1H), 4.25 (s, 1H), 4.25–4.22 (m, 2H), 3.92 (dd, *J* = 12.9, 1.7 Hz, 1H), 3.76 (s, 3H), 3.75–3.73 (m, 1H), 3.27 (dd, *J* = 13.9, 5.8 Hz, 1H), 3.13 (dd, *J* = 13.9, 4.9 Hz, 1H), 2.41 (s, 3H), 1.54 (s, 3H), 1.46 (s, 3H), 1.44 (s, 4H), 1.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 170.9, 166.5, 134.9, 129.1, 128.7, 127.4, 109.0, 101.0, 70.7, 70.0, 69.9, 69.4, 61.3, 55.0, 52.6, 36.5, 30.9, 26.5, 25.8, 25.3, 24.0, 20.8. HRMS (ESI-TOF): Anal. Calcd. For C₂₄H₃₄N₂O₁₀S+Na⁺: 565.1826, Found: 565.1827; IR (neat, cm⁻¹): ν 3325, 2989, 1744, 1548, 1154, 701.




***N*-(pyrrolidin-2-ylidene)-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfonamide (6e).** Petroleum ether/ ethylacetate = 1.2:1, white solid, 77.5 mg, 86% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 8.25 (s, 1H), 7.91–7.89 (m, 2H), 7.44–7.42 (m, 2H), 7.17–7.15 (m, 2H), 7.12–7.10 (m, 2H), 6.73 (s, 1H), 3.60 (m, 2H), 2.72 (m, 2H), 2.37 (s, 3H), 2.10–2.08 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 172.0, 145.0, 144.3, 143.9, 143.5, 143.1, 141.9, 141.8, 139.5, 129.6, 128.6, 127.4, 125.6, 125.1, 125.0, 122.3, 119.6, 117.0, 106.0, 46.4, 32.8, 21.2, 19.9. ¹⁹F NMR (376 MHz,

CDCl₃) δ -62.4. HRMS (ESI-TOF): Anal. Calcd. For C₂₁H₁₉F₃N₄O₂S+Na⁺: 471.1073, Found: 471.1065; IR (neat, cm⁻¹): ν 2969, 1600, 1235, 1133, 627.



1-(Benzo[d]isoxazol-3-yl)-N-(pyrrolidin-2-ylidene)methanesulfonamide (6f).


Petroleum ether/ ethylacetate = 1:1, white solid, 39.3 mg, 70% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, DMSO) δ 8.97 (s, 1H), 8.01–7.88 (m, 1H), 7.77–7.74 (m, 1H), 7.68–7.64 (m, 1H), 7.44–7.40 (m, 1H), 4.81 (s, 2H), 3.31 (t, *J* = 8.0 Hz, 3H), 2.60 (t, *J* = 8.0 Hz, 2H), 1.91–1.83 (m, 2H). ¹³C NMR (101 MHz, DMSO) δ 172.8, 162.6, 151.0, 130.4, 123.8, 123.6, 121.0, 109.5, 49.9, 44.8, 31.4, 20.4. HRMS (ESI-TOF): Anal. Calcd. For C₁₂H₁₃N₃O₃S+Na⁺: 302.0570, Found: 302.0581; IR (neat, cm⁻¹): ν 3119, 1632, 1605, 1294, 1139, 750.



Ethyl


2-(4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-(tosylimino)pyrrolidin-1-yl)acetate

(7a). Petroleum ether/ ethylacetate = 2.5:1, light yellow liquid, 82.28 mg, 81% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 7.78–7.76 (m, 2H), 7.27–7.23 (m, 2H), 6.79–6.77 (m, 1H), 6.73–6.69 (m, 2H), 4.75 (s, 1H), 4.30–4.26 (m, 1H), 4.21–4.13 (m, 3H), 3.87 (m, 1H), 3.81 (s, 3H), 3.63–3.54 (m, 3H), 3.09–3.06 (m, 1H), 2.39 (s, 3H), 1.89–1.82 (m, 6H), 1.60 (m, 2H), 1.24 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 170.0, 167.2, 149.1, 147.8, 142.1, 139.9, 133.3, 129.0, 126.3, 118.6, 113.4, 112.0, 80.3, 61.5, 57.1, 55.9, 45.8, 38.3, 38.2, 32.6, 32.5, 23.8, 21.2, 13.9. HRMS (ESI-TOF): Anal. Calcd. For C₂₇H₃₄N₂O₆S +H⁺: 515.2210, Found: 515.2218; IR (neat, cm⁻¹): ν 2926, 1742, 1570, 1141, 670.



Methyl *N*-(2-ethoxy-2-oxoethyl)-*N*-(1-(tosylimino)ethyl)-*L*-phenylalaninate (7b).


Petroleum ether/ ethylacetate = 2.5:1, light yellow liquid, 38.2 mg, 42% yield, *E/Z* = 1:1, $[\alpha]_{\text{D}}^{20} = -88.9$ (*c* 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.80–7.78 (m, 2H), 7.73–7.71 (m, 2H), 7.32–7.27 (m, 5H), 7.22–7.17 (m, 8H), 7.08–7.06 (m, 1H), 5.13 (t, *J* = 6.8 Hz, 1H), 4.68 (t, *J* = 7.2 Hz, 1H), 4.15–4.13 (m, 4H), 4.09–4.05 (m, 2H), 3.93 (q, *J* = 7.1 Hz, 2H), 3.69 (s, 3H), 3.55 (s, 3H), 3.23–3.15 (m, 2H), 3.09–3.00 (m, 2H), 2.46 (s, 3H), 2.42 (s, 3H), 2.39 (d, *J* = 1.2 Hz, 6H), 1.23 (t, *J* = 7.1 Hz, 3H), 1.09 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 169.9, 169.1, 167.6, 167.5, 166.4, 165.7, 142.2, 142.0, 140.3, 140.2, 136.3, 135.4, 129.0, 128.88, 128.86, 128.7, 128.5, 128.4, 127.4, 126.8, 126.2, 126.1, 61.9, 61.4, 61.1, 61.0, 52.7, 52.2, 46.9, 36.1, 35.0, 30.8, 21.4, 21.3, 18.0, 17.4, 13.9, 13.8. HRMS (ESI-TOF): Anal. Calcd. For C₂₃H₂₈N₂O₆S+Na⁺: 483.1560, Found: 483.1545; IR (neat, cm⁻¹): ν 2922, 1738, 1542, 1145, 686.



Ethyl (*S*)-1-(2-ethoxy-2-oxoethyl)-5-(tosylimino)pyrrolidine-2-carboxylate (7c).

Petroleum ether/ ethylacetate = 2:1, colourless liquid, 66.4 mg, 84% yield, *E/Z* = 3.3:1, $[\alpha]_{\text{D}}^{20} = 30.4$ (*c* 1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.78–7.75 (m, 2H), 7.26–7.24 (m, 2H), 4.70 (d, *J* = 17.8 Hz, 1H), 4.62 (d, *J* = 18.0 Hz, 0.3H), 4.48–4.41 (m, 1.3H), 4.22–4.07 (m, 5.32H), 3.84 (d, *J* = 17.8 Hz, 1H), 3.71 (d, *J* = 18.0 Hz, 0.3H), 3.21–3.02 (m, 2H), 2.56–2.43 (m, 1.9H), 2.42–2.40 (m, 3.56H), 2.25–2.11 (m, 1.32H), 1.27 (t, *J* = 7.1 Hz, 4.81H), 1.22 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ


175.4, 171.3, 171.2, 170.0, 168.6, 167.4, 142.3, 139.6, 129.0, 126.3, 61.9, 61.6, 61.4, 61.2, 59.3, 45.0, 42.8, 29.0, 28.8, 24.3, 22.6, 21.3, 14.0, 13.94, 13.89, 13.8. HRMS (ESI-TOF): Anal. Calcd. For $C_{18}H_{24}N_2O_6S+H^+$: 397.1428, Found: 397.1425; IR (neat, cm^{-1}): ν 2982, 1737, 1566, 1145, 671.



Ethyl

***N*-phenyl-*N*-((*E*)-1-((((3*aS*,5*aR*,8*aR*,8*bS*)-2,2,7,7-tetramethyltetrahydro-3*aH*-bis([1,3]dioxolo)[4,5-*b*:4',5'-*d*]pyran-3*a*-yl)methoxy)sulfonyl)imino)ethyl)glycinate**


(7d). Petroleum ether/ ethylacetate = 3.5:1, colourless liquid, 61.5 mg, 57% yield, *E/Z* > 99:1, $[\alpha]_D^{20} = -51.7$ (*c* 1, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$) δ 7.49–7.41 (m, 3H), 7.35–7.33 (m, 2H), 4.63 (dd, *J* = 7.9, 2.6 Hz, 1H), 4.58 (d, *J* = 16.8 Hz, 1H), 4.46 (d, *J* = 2.6 Hz, 1H), 4.37 (d, *J* = 16.9 Hz, 1H), 4.26–4.19 (m, 5H), 3.93 (dd, *J* = 13.0, 1.7 Hz, 1H), 3.75 (d, *J* = 12.9 Hz, 1H), 2.30 (s, 3H), 1.55 (s, 3H), 1.51 (s, 3H), 1.46 (s, 3H), 1.35 (s, 3H), 1.29 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 168.2, 167.4, 142.1, 130.1, 129.1, 127.4, 109.0, 108.9, 101.0, 70.7, 70.0, 69.9, 69.4, 61.6, 61.2, 53.6, 26.4, 25.8, 25.2, 24.0, 18.9, 14.0. HRMS (ESI-TOF): Anal. Calcd. For $C_{24}H_{34}N_2O_{10}S+Na^+$: 565.1826, Found: 565.1822; IR (neat, cm^{-1}): ν 2988, 1745, 1548, 1158, 701.



Ethyl

***N*-phenyl-*N*-(1-(((4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)sulfonyl)imino)ethyl)glycinate**

yl)imino)ethyl)glycinate (7e). Petroleum ether/ ethylacetate = 5:1, colourless liquid, 60.7 mg, 52% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.92 (m, 2H), 7.48–7.40 (m, 5H), 7.33–7.31 (m, 2H), 7.19–7.17 (m, 2H), 7.13–7.11 (m, 2H), 6.74 (s, 1H), 4.38 (s, 2H), 4.07 (q, *J* = 7.1 Hz, 2H), 2.38 (s, 3H), 2.32 (s, 3H), 1.17 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.6, 166.8, 145.0, 143.9, 143.5, 142.8, 142.0, 141.6, 139.5, 130.1, 129.6, 129.1, 128.6, 127.4, 127.3, 125.7, 125.1, 125.0, 122.4, 119.7, 117.0, 105.9, 105.9, 61.5, 53.9, 21.2, 19.3, 14.0. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.4. HRMS (ESI-TOF): Anal. Calcd. For C₂₉H₂₇F₃N₄O₄S+Na⁺: 607.1597, Found: 607.1583; IR (neat, cm⁻¹): ν 2984, 1744, 1540, 1088, 787.







Ethyl 2-(((benzo[d]isoxazol-3-ylmethyl)sulfonyl)imino)pyrrolidin-1-yl)acetate (7f). Petroleum ether/ ethylacetate = 1.5:1, light yellow solid, 23.3 mg, 32% yield, *E/Z* > 99:1. ¹H NMR (400 MHz, CDCl₃) δ 7.97–7.95 (m, 1H), 7.59–7.54 (m, 2H), 7.37–7.33 (m, 1H), 4.70 (s, 2H), 4.20 (q, *J* = 7.1 Hz, 2H), 4.07 (s, 2H), 3.52–3.51 (m, 2H), 2.94 (t, *J* = 7.4 Hz, 2H), 2.04–2.00 (m, 2H), 1.29 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 171.2, 166.9, 163.4, 150.4, 130.0, 123.8, 122.8, 121.1, 109.6, 61.7, 51.1, 50.2, 45.9, 30.9, 19.3, 14.0. HRMS (ESI-TOF): Anal. Calcd. For C₁₆H₁₉N₃O₅S +Na⁺: 388.0938, Found: 388.0935; IR (neat, cm⁻¹): ν 2923, 1733, 1572, 1295, 1125, 751.



References



(1) Toma, T.; Shimokawa, J.; Fukuyama, T. *Org. Lett.* **2007**, 9, 3195.



Spectroscopic data for products




















































































































































































































































XRD data of the compound 4a




Figure S1. ORTEP structural drawing of **4a**. (CCDC: 1827581)

Table S2. Crystallography data for **4a**.

complex	4a
Empirical formula	C ₁₅ H ₁₆ N ₂ O ₂ S
Formula weight(g mol ⁻¹)	288.36
Temperature	120 (2) K
Crystal system	Orthorhombic
space group	Pbca
Unit cell dimensions	a = 9.6494(8) Å
	b = 11.5395(7) Å
	c = 26.2979(15) Å
	α = 90 °
	β = 90 °
	γ = 90 °
Volume (Å ³)	2928.3(3)
Z	8
ρ(g cm ⁻³)	1.308
μ /mm ⁻¹	0.224
F(000)	1216.0

Crystal size(mm ³)	0.300 × 0.200 × 0.200
Radiation	MoK α (λ = 0.71073)
Theta range for data collection	6.196 °to 54.996 °
	-12<= <i>h</i> <=7
Limiting indices	-14<= <i>k</i> <=14
	-31<= <i>l</i> <=34
Reflections collected / unique	14673 / 3350
Data / restraints / parameters	3350 / 0 / 181
GOF	0.802
<i>R</i> 1, <i>wR</i> 2[I > 2 σ (I)]	<i>R</i> 1 = 0.0453
	<i>wR</i> 2 = 0.1122
<i>R</i> 1, <i>wR</i> 2(all data)	<i>R</i> 1 = 0.0798
	<i>wR</i> 2 = 0.1435
Largest diff. peak and hole(e $\text{\AA}^3$)	0.34 and -0.41

Table S3. Bond lengths [$\text{\AA}$] and angles [$^\circ$] for **4a**.

S(1)-O(2) 1.4394(18)	S(1)-O(1) 1.4403(18)	S(1)-N(1) 1.6132(19)	S(1)-C(5) 1.764(2)
N(1)-C(8) 1.318(3)	N(2)-C(8) 1.336(3)	N(2)-C(15) 1.429(3)	C(1)-C(2) 1.517(4)
C(2)-C(7) 1.384(4)	C(2)-C(3) 1.387(4)	C(3)-C(4) 1.384(4)	C(4)-C(5) 1.381(3)
C(5)-C(6) 1.386(3)	C(6)-C(7) 1.389(4)	C(8)-C(9) 1.495(3)	C(10)-C(15) 1.383(3)
C(10)-C(11) 1.387(3)	C(11)-C(12) 1.379(4)	C(12)-C(13) 1.385(4)	C(13)-C(14) 1.386(4)
C(14)-C(15) 1.391(3)	O(2)-S(1)-O(1) 116.61(11)	O(2)-S(1)-N(1) 104.44(10)	O(1)-S(1)-N(1) 113.52(10)
O(2)-S(1)-C(5) 107.53(11)	O(1)-S(1)-C(5) 107.69(11)	N(1)-S(1)-C(5) 106.48(10)	C(8)-N(1)-S(1) 121.51(17)
C(8)-N(2)-C(15) 128.1(2)	C(7)-C(2)-C(3) 118.5(2)	C(7)-C(2)-C(1) 121.0(3)	C(3)-C(2)-C(1) 120.5(3)
C(4)-C(3)-C(2) 121.0(3)	C(5)-C(4)-C(3) 119.5(2)	C(4)-C(5)-C(6) 120.7(2)	C(4)-C(5)-S(1) 118.54(18)
C(6)-C(5)-S(1) 120.78(19)	C(5)-C(6)-C(7) 118.9(2)	C(2)-C(7)-C(6) 121.4(3)	N(1)-C(8)-N(2) 119.0(2)
N(1)-C(8)-C(9) 125.7(2)	N(2)-C(8)-C(9) 115.4(2)	C(15)-C(10)-C(11) 119.3(2)	C(12)-C(12)-C(10) 121.2(2)
C(11)-C(12)-C(13) 119.2(2)	C(14)-C(13)-C(12) 120.4(2)	C(13)-C(14)-C(15) 119.8(2)	C(10)-C(15)-C(14) 120.1(2)
C(10)-C(15)-N(2) 122.7(2)	C(14)-C(15)-N(2) 117.1(2)		

XRD data of the compound **4l**




Figure S2. ORTEP structural drawing of **4l**. (CCDC: 1828634)

Table S4. Crystallography data for **4l**.

complex	4l
Empirical formula	C ₁₁ H ₁₄ N ₂ O ₂ S
Formula weight(g mol ⁻¹)	238.30
Temperature	296 (2) K
Crystal system	Monoclinic
space group	P2 (1) /c
Unit cell dimensions	a = 13.4264(17) Å
	b = 6.7926(9) Å
	c = 13.5926(17) Å
	α = 90 °
	β = 110.355(3) °
	γ = 90 °
Volume (Å ³)	1162.2(3)
Z	4
ρ(g cm ⁻³)	1.362
μ /mm ⁻¹	0.266
F(000)	504.0
Crystal size(mm ³)	0.200 × 0.200 × 0.180

Radiation	MoK α ($\lambda = 0.71073$)
Theta range for data collection	6.08 ° to 61.514 °
	-12 $\leq h \leq$ 17
Limiting indices	-9 $\leq k \leq$ 9
	-18 $\leq l \leq$ 14
Reflections collected / unique	8016 / 3195
Data / restraints / parameters	3195 / 0 / 146
GOF	1.016
$R1, wR2[I > 2\sigma(I)]$	$R1 = 0.0450$ $wR2 = 0.1333$
$R1, wR2(\text{all data})$	$R1 = 0.0572$ $wR2 = 0.1460$
Largest diff. peak and hole(e $\text{\AA}^3$)	0.34 and -0.35

Table S5. Bond lengths [$\text{\AA}$] and angles [$^\circ$] for **4l**.

C(1)-N(1) 1.3123(19)	C(1)-N(2) 1.313(2)	C(1)-C(2) 1.505(2)	C(2)-C(3) 1.522(3)
C(3)-C(4) 1.507(3)	C(4)-N(2) 1.456(2)	C(5)-C(6) 1.386(2)	C(5)-C(10) 1.389(2)
C(5)-S(1) 1.7565(15)	C(6)-C(7) 1.385(2)	C(7)-C(9) 1.387(3)	C(8)-C(9) 1.383(3)
C(8)-C(10) 1.384(2)	C(9)-C(11) 1.514(2)	N(1)-S(1) 1.6174(13)	O(1)-S(1) 1.4372(13)
O(2)-S(1) 1.4337(13)	N(1)-C(1)-N(2) 119.50(13)	N(1)-C(1)-C(2) 131.68(15)	N(2)-C(1)-C(2) 108.82(14)
C(1)-C(2)-C(3) 104.35(16)	C(4)-C(3)-C(2) 107.22(15)	N(2)-C(4)-C(3) 103.03(15)	C(6)-C(5)-C(10) 120.05(14)
C(6)-C(5)-S(1) 120.75(12)	C(10)-C(5)-S(1) 119.20(11)	C(7)-C(6)-C(5) 119.50(15)	C(6)-C(7)-C(9) 121.35(15)
C(9)-C(8)-C(10) 121.64(16)	C(8)-C(9)-C(7) 118.16(15)	C(8)-C(9)-C(11) 121.46(18)	C(7)-C(9)-C(11) 121.38(17)
C(8)-C(10)-C(5) 119.29(14)	C(1)-N(1)-S(1) 124.36(11)	C(1)-N(2)-C(4) 115.95(14)	O(2)-S(1)-O(1) 117.54(9)
O(2)-S(1)-N(1) 113.06(8)	O(1)-S(1)-N(1) 104.51(7)	O(2)-S(1)-C(5) 108.40(7)	O(1)-S(1)-C(5) 107.52(7)
N(1)-S(1)-C(5) 104.98(7)			

XRD data of the compound 5a




Figure S3. ORTEP structural drawing of **5a**. (CCDC: 1827580)

Table S6. Crystallography data for **5a**.

complex	5a
Empirical formula	C ₁₉ H ₂₂ N ₂ O ₄ S
Formula weight(g mol ⁻¹)	374.44
Temperature	120 (2) K
Crystal system	Orthorhombic
space group	Pna2(1)
Unit cell dimensions	a = 9.7504(5) Å
	b = 15.8797(9) Å
	c = 12.1655(8) Å
	α = 90 °
	β = 90 °
	γ = 90 °
Volume (Å ³)	1883.63(19)
Z	4
ρ(g cm ⁻³)	1.320
μ /mm ⁻¹	0.198
F(000)	792.0

Crystal size(mm ³)	0.60 × 0.20 × 0.20
Radiation	MoK α (λ = 0.71073)
Theta range for data collection	4.902 ° to 54.976 °
	-10 ≤ h ≤ 22
Limiting indices	-18 ≤ k ≤ 20
	-15 ≤ l ≤ 15
Reflections collected / unique	9778 / 4219
Data / restraints / parameters	4219 / 1 / 235
GOF	1.027
$R1, wR2[I > 2\sigma(I)]$	$R1 = 0.0566$ $wR2 = 0.1493$
$R1, wR2(\text{all data})$	$R1 = 0.0620$ $wR2 = 0.1567$
Largest diff. peak and hole(e Å ³)	1.11 and -0.55

Table S7. Bond lengths [Å] and angles [°] for **5a**.

S(1)-O(2) 1.442(3)	S(1)-O(1) 1.449(3)	S(1)-N(1) 1.606(3)	S(1)-C(5) 1.759(5)
N(1)-C(8) 1.311(5)	N(2)-C(8) 1.353(5)	N(2)-C(10) 1.434(5)	N(2)-C(16) 1.464(5)
O(3)-C(17) 1.195(5)	O(4)-C(17) 1.336(6)	O(4)-C(18) 1.455(6)	C(1)-C(2) 1.508(7)
C(2)-C(3) 1.381(7)	C(2)-C(7) 1.400(7)	C(3)-C(4) 1.400(6)	C(4)-C(5) 1.381(6)
C(5)-C(6) 1.393(5)	C(6)-C(7) 1.384(6)	C(8)-C(9) 1.503(6)	C(10)-C(15) 1.384(6)
C(10)-C(11) 1.397(5)	C(11)-C(12) 1.387(6)	C(12)-C(13) 1.392(6)	C(13)-C(14) 1.383(6)
C(14)-C(15) 1.388(6)	C(16)-C(17) 1.521(6)	C(18)-C(19) 1.423(10)	O(2)-S(1)-O(1) 115.46(19)
O(2)-S(1)-N(1) 111.12(19)	O(1)-S(1)-N(1) 113.17(17)	O(2)-S(1)-C(5) 108.29(19)	O(1)-S(1)-C(5) 107.76(19)
N(1)-S(1)-C(5) 99.67(18)	C(8)-N(1)-S(1) 121.9(3)	C(8)-N(2)-C(10) 122.4(4)	C(8)-N(2)-C(16) 118.0(3)
C(10)-N(2)-C(16) 119.5(3)	C(17)-O(4)-C(18) 117.5(4)	C(3)-C(2)-C(7) 118.8(4)	C(3)-C(2)-C(1) 120.9(4)
C(7)-C(2)-C(1) 120.3(4)	C(2)-C(3)-C(4) 120.8(4)	C(5)-C(4)-C(3) 119.7(4)	C(4)-C(5)-C(6) 120.2(4)
C(4)-C(5)-S(1) 119.1(3)	C(6)-C(5)-S(1) 120.6(3)	C(7)-C(6)-C(5) 119.6(4)	C(6)-C(7)-C(2) 120.9(4)
N(1)-C(8)-N(2) 115.6(4)	N(1)-C(8)-C(9) 126.3(4)	N(2)-C(8)-C(9) 118.1(4)	C(15)-C(10)-C(11) 120.5(4)
C(15)-C(10)-N(2) 119.9(4)	C(11)-C(10)-N(2) 119.5(4)	C(12)-C(11)-C(10) 119.2(4)	C(11)-C(12)-C(13) 120.4(4)
C(14)-C(13)-C(12) 119.6(4)	C(13)-C(14)-C(15) 120.6(4)	C(10)-C(15)-C(14) 119.5(4)	N(2)-C(16)-C(17) 111.8(3)

O(3)-C(17)-O(4) 125.8(4)	O(3)-C(17)-C(16) 124.4(4)	O(4)-C(17)-C(16) 109.7(4)	C(19)-C(18)-O(4) 113.4(4)
--------------------------	---------------------------	---------------------------	---------------------------

XRD data of the compound 5k




Figure S4. ORTEP structural drawing of **5k**. (CCDC: 1827576)

Table S8. Crystallography data for **5k**.

complex	5k
Empirical formula	C ₁₅ H ₂₀ N ₂ O ₄ S
Formula weight(g mol ⁻¹)	324.39
Temperature	120 (2) K
Crystal system	Monoclinic
space group	P2 (1) /n
Unit cell dimensions	a = 7.6307(7) Å
	b = 7.7492(8) Å
	c = 26.486(2) Å
	α = 90 °
	β = 91.851(3) °
	γ = 90 °

Volume (Å ³)	1565.4(2)
Z	4
ρ(g cm ⁻³)	1.376
μ /mm ⁻¹	0.226
F(000)	688.0
Crystal size(mm ³)	0.20 × 0.20 × 0.20
Radiation	MoKα (λ = 0.71073)
Theta range for data collection	5.478 ° to 55.274 °
	-9 ≤ h ≤ 9
Limiting indices	-9 ≤ k ≤ 10
	-34 ≤ l ≤ 34
Reflections collected / unique	13904 / 3601
Data / restraints / parameters	3601 / 0 / 199
GOF	0.996
<i>R</i> 1, <i>wR</i> 2[I > 2σ(<i>I</i>)]	<i>R</i> 1 = 0.0605 <i>wR</i> 2 = 0.1212
<i>R</i> 1, <i>wR</i> 2(all data)	<i>R</i> 1 = 0.1491 <i>wR</i> 2 = 0.1599
Largest diff. peak and hole(e Å ³)	0.37 and -0.45

Table S9. Bond lengths [Å] and angles [°] for **5k**.

S(1)-O(1) 1.441(2)	S(1)-O(2) 1.440(2)	S(1)-N(1) 1.611(3)	S(1)-C(5) 1.758(3)
N(1)-C(8) 1.315(4)	N(2)-C(8) 1.332(4)	N(2)-C(12) 1.452(4)	N(2)-C(11) 1.1468(4)
O(3)-C(13) 1.206(4)	O(4)-C(13) 1.338(4)	O(3)-C(14) 1.464(4)	C(1)-C(2) 1.508(5)
C(2)-C(3) 1.394(5)	C(2)-C(7) 1.389(5)	C(3)-C(4) 1.382(5)	C(4)-C(5) 1.389(5)
C(5)-C(6) 1.386(4)	C(6)-C(7) 1.391(5)	C(8)-C(9) 1.512(4)	C(9)-C(10) 1.527(4)
C(10)-C(11) 1.531(5)	C(12)-C(13) 1.509(5)	C(14)-C(15) 1.492(4)	O(1)-S(1)-O(2) 116.87(14)
O(1)-S(1)-N(1) 113.93(14)	O(2)-S(1)-N(1) 105.57(15)	O(1)-S(1)-C(5) 108.04(15)	O(2)-S(1)-C(5) 107.73(14)
N(1)-S(1)-C(5) 103.79(14)	C(8)-N(1)-S(1) 122.2(2)	C(8)-N(2)-C(12) 122.9(3)	C(8)-N(2)-C(11) 113.7(3)
C(12)-N(2)-C(11) 123.1(3)	C(13)-O(4)-C(14) 116.4(2)	C(3)-C(2)-C(7) 118.6(3)	C(3)-C(2)-C(1) 120.2(3)
C(7)-C(2)-C(1) 121.2(3)	C(4)-C(3)-C(2) 120.5(3)	C(3)-C(4)-C(5) 120.4(3)	C(4)-C(5)-C(6) 119.8(3)
C(4)-C(5)-S(1) 120.3(2)	C(6)-C(5)-S(1) 119.9(3)	C(7)-C(6)-C(5) 119.5(3)	C(6)-C(7)-C(2) 121.2(3)

N(1)-C(8)-N(2) 119.7(3)	N(1)-C(8)-C(9) 131.8(3)	N(2)-C(8)-C(9) 108.5(3)	C(8)-C(9)-C(10) 104.1(3)
C(11)-C(10)-C(9) 103.9(3)	N(2)-C(11)-C(10) 102.2(3)	N(2)-C(12)-C(13) 113.2(3)	O(3)-C(13)-O(4) 124.7(3)
O(3)-C(13)-C(12) 126.2(3)	O(4)-C(13)-C(12) 109.2(3)	O(4)-C(14)-C(15) 107.5(3)	
